We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israel-based Medasense Biometrics has received de novo marketing authorization from the FDA for its PMD 200 device that monitors a patient’s pain level while under anesthesia, using artificial intelligence (AI) algorithms to convert data into a patient’s “signature of pain.”
After filing a Special 501(k) requesting a change to its existing device clearance, Signifier Medical Technologies received FDA’s approval to remove a contraindication for its eXciteOSA daytime therapy for obstructive sleep apnea (OSA).
BD’s Onclarity HPV Assay — the only FDA approved test that looks for multiple types of human papillomavirus virus (HPV) individually — can now be marketed for use with two different pap tests, Hologic ThinPrep and BD SurePath Liquid.
Perfuze announced that its Millipede 088 Access Catheter — which gained Breakthrough Device status from the FDA in 2019 — has now been cleared by the agency to treat acute ischemic stroke and has been used successfully in surgeries at two U.S. hospitals.